ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa

Introduction: Hidradenitis suppurativa (HS) is a chronic disease that causes painful skin lumps and scarring in the skin. In an important number of patients, the disease starts in adolescence. Adalimumab was the first biologic drug approved in adolescents with HS, yet approval was done on a model-ba...

Full description

Bibliographic Details
Authors: Grau-Pérez, M, Ciudad, C, Molina-Leyva, A, Martorell, A, Vilarrasa, E, Albert, I, Garcias-Ladaria, J, Melgosa, FJ, Rivera, R, Campos, M, Haselgruber, S, Ochando, G, Pascual, JC, García-Ruiz, R, Alfageme, F
Format: article
Status:Published version
Publication Date:2025
Country:España
Institution:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repository:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p19394
Online Access:https://fisabio.portalinvestigacion.com/publicaciones/19394
Access Level:Open access
Keyword:Dermatology
Hidradenitis suppurativa
Drug response
Adalimumab
Adolescence
Pediatric
id ES_0aeb8d038ce30395dd14aaa4e38837f1
oai_identifier_str oai:fisabio.fundanetsuite.com:p19394
network_acronym_str ES
network_name_str España
repository_id_str
spelling ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis SuppurativaGrau-Pérez, MCiudad, CMolina-Leyva, AMartorell, AVilarrasa, EAlbert, IGarcias-Ladaria, JMelgosa, FJRivera, RCampos, MHaselgruber, SOchando, GPascual, JCGarcía-Ruiz, RAlfageme, FDermatologyHidradenitis suppurativaDrug responseAdalimumabAdolescencePediatricIntroduction: Hidradenitis suppurativa (HS) is a chronic disease that causes painful skin lumps and scarring in the skin. In an important number of patients, the disease starts in adolescence. Adalimumab was the first biologic drug approved in adolescents with HS, yet approval was done on a model-based extrapolation from other diseases. Data regarding the effectiveness and safety of adalimumab in HS in this age group is lacking. Our objective was to describe the effectiveness and safety of adalimumab in adolescents with moderate-to-severe HS. Methods: Retrospective multicenter case series. HS units across Spain were invited to participate, including all patients starting adalimumab in adolescence. Demographic, clinical, and treatment-related characteristics were retrieved. Effectiveness was measured as the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at 6 months. Safety was assessed by means of quantification and description of side effects over time. Results: A total of 65 patients from 9 HS units were included. Mean age at adalimumab start was 15.5 years. A total of 76.9% of patients achieved HiSCR at 6 months. Side effects were observed in 7 patients, 3 of them requiring drug discontinuation, with full recovery. The adult dosage (80 mg every other week [EOW]/40 mg every week) was more frequently used. The median drug survival time for adalimumab was 5.6 years (25th percentile: 2.9 years), and the recommended adolescent dosage (40 mg EOW) was associated with a need for intensification (p < 0.001). The main limitations of the study are the lack of a comparison group and the retrospective design. Conclusion: Adalimumab showed a similar safety profile in adolescents with moderate-to-severe HS as in adults, with better effectiveness data.KARGER2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/19394DERMATOLOGYISSN: 10188665ISSNe: 14219832reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p193942026-06-11T12:45:17Z
dc.title.none.fl_str_mv ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa
title ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa
spellingShingle ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa
Grau-Pérez, M
Dermatology
Hidradenitis suppurativa
Drug response
Adalimumab
Adolescence
Pediatric
title_short ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa
title_full ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa
title_fullStr ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa
title_full_unstemmed ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa
title_sort ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa
dc.creator.none.fl_str_mv Grau-Pérez, M
Ciudad, C
Molina-Leyva, A
Martorell, A
Vilarrasa, E
Albert, I
Garcias-Ladaria, J
Melgosa, FJ
Rivera, R
Campos, M
Haselgruber, S
Ochando, G
Pascual, JC
García-Ruiz, R
Alfageme, F
author Grau-Pérez, M
author_facet Grau-Pérez, M
Ciudad, C
Molina-Leyva, A
Martorell, A
Vilarrasa, E
Albert, I
Garcias-Ladaria, J
Melgosa, FJ
Rivera, R
Campos, M
Haselgruber, S
Ochando, G
Pascual, JC
García-Ruiz, R
Alfageme, F
author_role author
author2 Ciudad, C
Molina-Leyva, A
Martorell, A
Vilarrasa, E
Albert, I
Garcias-Ladaria, J
Melgosa, FJ
Rivera, R
Campos, M
Haselgruber, S
Ochando, G
Pascual, JC
García-Ruiz, R
Alfageme, F
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Dermatology
Hidradenitis suppurativa
Drug response
Adalimumab
Adolescence
Pediatric
topic Dermatology
Hidradenitis suppurativa
Drug response
Adalimumab
Adolescence
Pediatric
description Introduction: Hidradenitis suppurativa (HS) is a chronic disease that causes painful skin lumps and scarring in the skin. In an important number of patients, the disease starts in adolescence. Adalimumab was the first biologic drug approved in adolescents with HS, yet approval was done on a model-based extrapolation from other diseases. Data regarding the effectiveness and safety of adalimumab in HS in this age group is lacking. Our objective was to describe the effectiveness and safety of adalimumab in adolescents with moderate-to-severe HS. Methods: Retrospective multicenter case series. HS units across Spain were invited to participate, including all patients starting adalimumab in adolescence. Demographic, clinical, and treatment-related characteristics were retrieved. Effectiveness was measured as the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at 6 months. Safety was assessed by means of quantification and description of side effects over time. Results: A total of 65 patients from 9 HS units were included. Mean age at adalimumab start was 15.5 years. A total of 76.9% of patients achieved HiSCR at 6 months. Side effects were observed in 7 patients, 3 of them requiring drug discontinuation, with full recovery. The adult dosage (80 mg every other week [EOW]/40 mg every week) was more frequently used. The median drug survival time for adalimumab was 5.6 years (25th percentile: 2.9 years), and the recommended adolescent dosage (40 mg EOW) was associated with a need for intensification (p < 0.001). The main limitations of the study are the lack of a comparison group and the retrospective design. Conclusion: Adalimumab showed a similar safety profile in adolescents with moderate-to-severe HS as in adults, with better effectiveness data.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/19394
url https://fisabio.portalinvestigacion.com/publicaciones/19394
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv KARGER
publisher.none.fl_str_mv KARGER
dc.source.none.fl_str_mv DERMATOLOGY
ISSN: 10188665
ISSNe: 14219832
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403191498506240
score 15,812429

Similar Items